阿斯利康全球研发中国博士后计划

• Clarifying Lp(a)'s role in atherothrombotic events, focusing on comprehensive lipid profiling, predictive biomarkers and interaction pathways

• Multi-omic profiling of visceral adipose tissue (VAT) to delineate its molecular architecture, distinct biomarkers, and master regulatory pathways driving the transition from metabolic health to obesity-related dysfunction

• Characterizing aldosterone profile and related pathway in health population and chronic kidney patients

• Enabling hit discovery technologies and novel modalities to target the undruggable proteins

• Integrated omics data generation in advanced cell models to guide target selection and compound profiling

• CT and novel biomarkers in respiratory diseases: Explore CT and novel biomarkers' progonostics application in different risk population segmentation in COPD and NCFBE

IBD - Fibrosis and fistulae in IBD

• Fibroblast heterogeneity; biomarkers to predict development of fibrostenosing CD and/or strictures; pathways to prevent/reverse intestinal fibrosis

• Specific cell type expression and/or characterization of fibroblasts subsets showing and/or predicting responsive to IL-11 / TL1A; and the differentiation between these pathways and that of TGFB

RA – Very Early RA (or Pre-RA) and Difficult to Treat RA

• Clinical characterization, immunoprofiling, and multiomic profiling of VERA subjects to elucidate journey within healthcare system, current treatment patterns, biomarkers to predict progression to established RA; pathogenic pathways and drivers of established RA in VERA;

• Clinical characterization, immunoprofiling, and multiomic profiling of D2T RA to elucidate the burden, current treatment patterns, pathogenic pathways and drivers of D2T RA or multi-drug resistance.

B cell and T cell biology in autoimmune diseases

• Identify surface markers that discriminate autoreactive/pathogenic T cells from physiologic T cell populations across MS, RA, and IBD intervention

• T cell plasticity and immune tolerance; transcriptional regulators of Treg stability and function; engineer of antigen-specific Tregs (TCR/CAR).

• Targets beyond CD20; B cell subsets heterogeneity and novel subsets; identify autoreactive B-cell clones with strategies for selective depletion

Rare renal diseases

• Novel drug targets and therapeutic concepts

• Developing predictive and prognosis biomarkers or animal model to identify high-risk progressive patients in IgA nephropathy or crescentic GN with precision treatment approach

• Exploring the underlined pathogenesis in podocyte injury relevant kidney disease especially related to complement pathway and could be validated with available compounds

• Studying complement or non-complement mediated pathophysiology and disease progression of genetic kidney disease and ANCA-Associated Vasculitis

• Characterizing predictive biomarkers and patient profiles in transplant related kidney disease especially with relapsed GN post-transplant

Rare neurodegenerative diseases

• Novel drug targets and therapeutic concepts.

• Developing predictive and prognostic complex biomarkers in Glioblastoma which include pathology, radiology and molecular assessments to predict response to immune therapies

• Developing translational biomarkers predictive of response to innovative treatment in neurodegenerative diseases

Rare cardiomyopathies

• Novel drug targets and therapeutic concepts

Enabling therapeutic platforms and technologies for rare diseases:

• Improved methodologies for drug delivery and therapeutic intervention (in vivo CAR-T modification, genomic therapies, ligand-conjugates and T-cell engagers)

• Tissue‑targeted delivery science for rare diseases: Delivery systems and targeting moieties to heart, CNS, kidney, cardiac and skeletal muscle

• Investigating liver metastatic microenvironment and exploring the therapeutic targets or pathways to treat liver metastases that have the potential to improve metastatic patients’ outcome

• Studying the elements that lead to patient benefit with TCEs, e.g., i) role of different T cell subtypes; ii) interaction with TME; iii) T cell trafficking/availability

• Discovery of new armoring mechanisms for CAR-T in solid tumors

• The relation between MTAP loss and TME (tumor microenvironment) in solid tumors

• Exploring the tumor heterogeneity, target expression, resistance / sensitivity biomarker and association with TME for ADC therapy

• Study of immunogenic cell death and how this can sensitize immunotherapy

• Developing predictive and prognostic complex biomarkers in gastric cancer which include pathology, radiology and molecular assessments in response to neoadjuvant immune-therapies

• Exploring the adaptive pathways that underly resistance to KRAS inhibition and potential combination in PDAC (Pancreatic ductal adenocarcinoma)

• Characterizing gastric cancer/ esophageal squamous cell carcinoma-specific surface protein expression and their post-translational modifications

• Characterizing the early and metastatic urothelial cancers in China on protein, RNA transcript and genomics levels as it relates to response to immunotherapy